aTyr Secures FDA Agreement for Phase 3, Has $50.3 Million in Liquidity
Key Facts
aTyr Pharma reported third-quarter 2026 results and said it had reached an agreement with the U.S. Food and Drug Administration on the design of a proposed global Phase 3 study of efzofitimod for pulmonary sarcoidosis. The regulatory step paves the way to complete initial study-related activities, but the company said it would prioritize strategic partnerships or licensing arrangements to advance the study after those activities. Chief Executive Sanjay S. Shukla said, "Our best path to advance efzofitimod is to prioritize strategic partnerships." The approach puts funding and a potential partner at the center of the program's next step, alongside trial preparation. The company disclosed in September that the proposed study would target approximately 372 patients, with the primary endpoint measuring change in forced vital capacity at Week 48.
The agreement follows publication in The Lancet Respiratory Medicine of results from the Phase 3 EFZO-FIT trial, a previous study of efzofitimod for pulmonary sarcoidosis. EFZO-FIT did not meet its primary endpoint, which assessed a reduction in daily corticosteroid dose at Week 48. The mean daily dose was 2.79 mg with efzofitimod at 5 mg per kilogram, compared with 3.52 mg with placebo. The difference was not statistically significant, with a p-value of 0.3313. According to the company's disclosure, the proposed study is based on an analysis of a subgroup from the previous trial that included patients with pulmonary restriction. The company said this group showed clinical benefit in forced vital capacity and improvement in multiple patient-reported measures compared with placebo.
Advancing the proposed study will require additional funding, according to the company's filing with the U.S. Securities and Exchange Commission. aTyr said options include issuing equity or debt, obtaining grants, or entering into a collaboration, strategic partnership or licensing arrangement. In its results statement, the company said it preferred partnerships or licensing after completing initial study-related activities. This reliance on a future financing arrangement comes as the company held $50.3 million in cash and cash equivalents, restricted cash and available-for-sale investments on September 30, 2026. The company said that, based on its current plans and operating forecasts, this balance would fund its current operations through late 2028. That runway limits the company's stated immediate need to fund current operations, but does not eliminate the need for additional capital to advance Phase 3.
Financial data showed cash, restricted cash and available-for-sale investments fell from $80.922 million on December 31, 2025, to $50.253 million on September 30, 2026. In the third quarter, the company recorded research and development expenses of $10.4 million, mostly related to the Phase 2 EFZO-CONNECT study and its preclinical candidates. General and administrative expenses were $8.3 million in the same quarter. These items provide a picture of operating expenses during a period in which the company is seeking to advance its programs, including preparation for the Phase 3 path. The available information did not include annual or quarterly comparisons for these expenses, so the figures reported here are limited to third-quarter 2026 values.
Alongside its efzofitimod program, aTyr announced a research collaboration with Montefiore Einstein to study the antibody ATYR2810 preclinically in pediatric osteosarcoma. The company did not provide a timeline for results from the collaboration or additional details on its study design in its results announcement. The next announced milestone for the EFZO-CONNECT program is full results expected in the second quarter of 2027. The company said those results will include clinical and laboratory measures, as well as an exposure-response analysis. The data provide a timeline for tracking the study, while a partnership or licensing arrangement remains the path the company said it would prioritize to advance Phase 3 after the initial activities.